S-1 in gastric cancer: a comprehensive review

@article{Maehara2003S1IG,
  title={S-1 in gastric cancer: a comprehensive review},
  author={Yoshihiko Maehara},
  journal={Gastric Cancer},
  year={2003},
  volume={6},
  pages={2-8}
}
The current basic and clinical studies of S-1 (TS-1®) were reviewed. S-1 is a novel oral dihydropyrimidine dehydrogenase (DPD) inhibitory fluoropyrimidine (DIF) based on a biochemical modulation of 5-fluorouracil (5-FU); S-1 contains tegafur (FT) and two types of enzyme inhibitor; 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate (Oxo) in a molar ratio of 1 : 0.4 : 1. In pharmacokinetic studies, S-1 showed high 5-FU concentration in blood for long periods of time. In a combined… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 44 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 51 references

Uracil-tegafur in gastric carcinoma: a comprehensive review.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 1998
View 3 Excerpts
Highly Influenced

A phase I and PK study of S-1 and irinotecan (CPT-11) in patients with advanced gastric cancer (AGC) (abstract)

Y Komatsu, H Takeda, +3 authors T Miyagishima
Proc Am Soc Clin Oncol • 2002
View 1 Excerpt

Phase I study of CPT-11 plus S-1 in patients with metastatic gastric cancer (abstract)

H Narahara, H Takiuchi, T Tsujinaka, H Furukawa, T. Taguchi
Proc Am Soc Clin Oncol 2002;21:170a • 2002
View 1 Excerpt

Similar Papers

Loading similar papers…